FEATURED COMPANIES
- 4SC
- Bayer
- Boston Pharmaceuticals
- Catalyst pharma
- Pierre Fabre
- selection
This “Potassium channel antagonists- Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Potassium channel antagonists: Overview
Potassium channel blockers are agents which interfere with conduction through potassium channels. Potassium is the chief ion in the repolarization. At the end of depolarization, potassium efflux occurs following the opening of the potassium channels. This group of drugs binds to the channel which is responsible for the potassium movement and blocks it. Once the blocking has happened, the refractory period increases.
Function - Potassium-channel blockers comprise the Class III antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the potassium channels that are responsible for phase 3 repolarization. Therefore, blocking these channels slows (delays) repolarization, which leads to an increase in action potential duration and an increase in the effective refractory period (ERP).
Potassium channel antagonists - Potassium Channel antagonist act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of Action potentials. They are used as Anti-Arrhythmia agents and Vasodilator agents.
Potassium channel antagonists Emerging Drugs Chapters
This segment of the Potassium channel antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Potassium channel antagonists Emerging Drugs
Amifampridine: BioMarin
Amifampridine (Firdapse) is an orally administered potassium channel antagonist and acetylcholine release stimulant that has been developed by BioMarin. It is being studied in Phase III clinical trials for Myasthenia gravis. The drug has also received orphan drug designation for Myasthenia gravis, Lambert-Eaton myasthenic syndrome; Congenital myasthenic syndromes.
Sleep apnoea therapeutic: Bayer
Sleep apnoea therapeutic is a potassium channel antagonists, currently being studied in Phase II stage of development for the treatment of patients with Sleep apnoea syndrome.
Potassium channel antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Potassium channel antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Potassium channel antagonists
There are approx. 10+ key companies which are developing the Potassium channel antagonists. The companies which have their Potassium channel antagonists drug candidates in the most advanced stage, i.e. Phase III include, BioMarin.
Phases
This report covers around 10+ products under different phases of clinical development like
Potassium channel antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Potassium channel antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Potassium channel antagonists drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Potassium channel antagonists R&D. The therapies under development are focused on novel approaches for Potassium channel antagonists.
Potassium channel antagonists Report Insights
Current Scenario and Emerging Therapies:
This report will be delivered within 2 business days.
Geography Covered
- Global coverage
Potassium channel antagonists: Overview
Potassium channel blockers are agents which interfere with conduction through potassium channels. Potassium is the chief ion in the repolarization. At the end of depolarization, potassium efflux occurs following the opening of the potassium channels. This group of drugs binds to the channel which is responsible for the potassium movement and blocks it. Once the blocking has happened, the refractory period increases.
Function - Potassium-channel blockers comprise the Class III antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the potassium channels that are responsible for phase 3 repolarization. Therefore, blocking these channels slows (delays) repolarization, which leads to an increase in action potential duration and an increase in the effective refractory period (ERP).
Potassium channel antagonists - Potassium Channel antagonist act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of Action potentials. They are used as Anti-Arrhythmia agents and Vasodilator agents.
Potassium channel antagonists Emerging Drugs Chapters
This segment of the Potassium channel antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Potassium channel antagonists Emerging Drugs
Amifampridine: BioMarin
Amifampridine (Firdapse) is an orally administered potassium channel antagonist and acetylcholine release stimulant that has been developed by BioMarin. It is being studied in Phase III clinical trials for Myasthenia gravis. The drug has also received orphan drug designation for Myasthenia gravis, Lambert-Eaton myasthenic syndrome; Congenital myasthenic syndromes.
Sleep apnoea therapeutic: Bayer
Sleep apnoea therapeutic is a potassium channel antagonists, currently being studied in Phase II stage of development for the treatment of patients with Sleep apnoea syndrome.
Potassium channel antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Potassium channel antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Potassium channel antagonists
There are approx. 10+ key companies which are developing the Potassium channel antagonists. The companies which have their Potassium channel antagonists drug candidates in the most advanced stage, i.e. Phase III include, BioMarin.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Potassium channel antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Potassium channel antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Potassium channel antagonists drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Potassium channel antagonists R&D. The therapies under development are focused on novel approaches for Potassium channel antagonists.
Potassium channel antagonists Report Insights
- Potassium channel antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Potassium channel antagonists drugs?
- How many Potassium channel antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Potassium channel antagonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Potassium channel antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Potassium channel antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- 4SC
- Bayer
- Boston Pharmaceuticals
- Catalyst pharma
- Pierre Fabre
- selection
Introduction
Executive Summary
Potassium channel antagonists: Overview
In-depth Commercial Assessment
Potassium channel antagonists Key Products
Potassium channel antagonists- Unmet Needs
Potassium channel antagonists- Market Drivers and Barriers
Potassium channel antagonists- Future Perspectives and Conclusion
Potassium channel antagonists Analyst Views
Potassium channel antagonists Key Companies
Appendix
List of Tables
Table 1 Total Products for Potassium channel antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Potassium channel antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Potassium channel antagonists: Overview
- Structure
- Mechanism of Action
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Potassium channel antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Potassium channel antagonists Key Products
Potassium channel antagonists- Unmet Needs
Potassium channel antagonists- Market Drivers and Barriers
Potassium channel antagonists- Future Perspectives and Conclusion
Potassium channel antagonists Analyst Views
Potassium channel antagonists Key Companies
Appendix
List of Tables
Table 1 Total Products for Potassium channel antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Potassium channel antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
- Bayer
- 4SC
- selection
- Boston Pharmaceuticals
- Pierre Fabre
- Catalyst pharma
Note: Product cover images may vary from those shown
